PL2865387T3 - Pobudzenie odpowiedzi odpornościowej - Google Patents

Pobudzenie odpowiedzi odpornościowej

Info

Publication number
PL2865387T3
PL2865387T3 PL15152408T PL15152408T PL2865387T3 PL 2865387 T3 PL2865387 T3 PL 2865387T3 PL 15152408 T PL15152408 T PL 15152408T PL 15152408 T PL15152408 T PL 15152408T PL 2865387 T3 PL2865387 T3 PL 2865387T3
Authority
PL
Poland
Prior art keywords
priming
immune response
immune
response
Prior art date
Application number
PL15152408T
Other languages
English (en)
Inventor
Peter Holst
Allan Thomsen
Jan Christensen
Mirjana Grujic
Original Assignee
Københavns Universitet (University Of Copenhagen)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Københavns Universitet (University Of Copenhagen) filed Critical Københavns Universitet (University Of Copenhagen)
Publication of PL2865387T3 publication Critical patent/PL2865387T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL15152408T 2008-11-21 2009-11-20 Pobudzenie odpowiedzi odpornościowej PL2865387T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200801638 2008-11-21
PCT/DK2009/050310 WO2010057501A1 (en) 2008-11-21 2009-11-20 Priming of an immune response
EP09760468A EP2355842A1 (en) 2008-11-21 2009-11-20 Priming of an immune response
EP15152408.9A EP2865387B1 (en) 2008-11-21 2009-11-20 Priming of an immune response

Publications (1)

Publication Number Publication Date
PL2865387T3 true PL2865387T3 (pl) 2019-12-31

Family

ID=40823418

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15152408T PL2865387T3 (pl) 2008-11-21 2009-11-20 Pobudzenie odpowiedzi odpornościowej

Country Status (20)

Country Link
US (4) US20110293704A1 (pl)
EP (3) EP2355842A1 (pl)
JP (4) JP2012509071A (pl)
CN (3) CN104404068A (pl)
AU (1) AU2009317691A1 (pl)
BR (1) BRPI0921927B8 (pl)
CA (1) CA2743229A1 (pl)
CY (1) CY1122117T1 (pl)
DK (1) DK2865387T3 (pl)
ES (1) ES2743677T3 (pl)
HK (1) HK1209645A1 (pl)
HR (1) HRP20191594T1 (pl)
HU (1) HUE045093T2 (pl)
IL (4) IL212914A0 (pl)
LT (1) LT2865387T (pl)
PL (1) PL2865387T3 (pl)
PT (1) PT2865387T (pl)
RU (2) RU2011125306A (pl)
SI (1) SI2865387T1 (pl)
WO (1) WO2010057501A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599605A (en) 2007-02-19 2013-11-29 Marinepolymer Tech Inc Hemostatic compositions and therapeutic regimens
BR112012030794B1 (pt) * 2010-06-04 2019-11-26 Inserm ( Institut National De La Santé Et De La Recherche Médicale) Novos compostos imunoadjuvantes e usos dos mesmos
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
EP2766385A2 (en) * 2011-10-12 2014-08-20 Novartis AG Cmv antigens and uses thereof
EP2788767B1 (en) 2011-12-07 2017-09-06 Belgian Volition SPRL Method for detecting nucleosome adducts
US9962436B2 (en) * 2012-07-26 2018-05-08 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
AU2014228489B2 (en) 2013-03-15 2018-11-15 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10576143B2 (en) 2013-03-15 2020-03-03 Glaxosmithkline Biologicals Sa Poxviral vaccines
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
CN105451779A (zh) * 2013-08-21 2016-03-30 库瑞瓦格股份公司 增加rna编码蛋白表达的方法
GB201321384D0 (en) * 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
BR112016015105A8 (pt) * 2013-12-27 2018-04-24 Var2 Pharmaceuticals Aps conjugados var2csa-droga
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
RS62860B1 (sr) 2014-09-17 2022-02-28 Zymeworks Inc Citotoksična i antimitotička jedinjenja, i postupci upotrebe istih
US11623001B2 (en) * 2015-10-12 2023-04-11 Nantomics, Llc Compositions and methods for viral cancer neoepitopes
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
EP3504230A1 (en) * 2016-08-23 2019-07-03 GlaxoSmithKline Biologicals SA Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
BE1024774B1 (fr) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201704417D0 (en) * 2017-03-20 2017-05-03 Univ Copenhagen Improved li vaccine adjuvant
WO2019012091A1 (en) * 2017-07-12 2019-01-17 Nouscom Ag NEOANTIGEN-BASED VACCINE COMPOSITION FOR THE TREATMENT OF CANCER
CN118888004A (zh) 2017-10-10 2024-11-01 磨石生物公司 使用热点进行的新抗原鉴别
KR102747530B1 (ko) * 2017-11-03 2024-12-27 노우스콤 아게 백신 t 세포 인핸서
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
CN108285885A (zh) * 2017-12-28 2018-07-17 中国农业大学 一种霍乱弧菌菌影制备方法及其在家禽疫苗中的应用
MX2020013553A (es) 2018-06-12 2021-02-26 Glaxosmithkline Biologicals Sa Polinucleotidos y polipeptidos de adenovirus.
IL282429B2 (en) * 2018-10-19 2025-04-01 Nouscom Ag TELEOST invariant chain as a cancer vaccine
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
RU2725493C2 (ru) * 2018-12-28 2020-07-02 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Система для стабильной экспрессии опухоль-ассоциированных антигенов на основе лентивирусного вектора
JP2022524007A (ja) 2019-03-05 2022-04-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｂ型肝炎免疫化レジメンおよび組成物
CN111729093B (zh) * 2020-06-29 2022-05-24 南京超维景生物科技有限公司 一种造影剂成膜剂组合物、造影剂成膜脂液、造影剂及其制备方法
EP4137153A1 (en) 2021-08-18 2023-02-22 Sirion Biotech GmbH Therapeutic papilloma virus vaccines
CN120456919A (zh) 2022-12-19 2025-08-08 葛兰素史克生物有限公司 乙型肝炎组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US587673A (en) 1897-08-03 higgins
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
JP2682061B2 (ja) 1988-10-07 1997-11-26 藤沢薬品工業株式会社 ペプチドの分子内ジスルフィド結合の形成法
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
US5876735A (en) 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
AU7690896A (en) * 1995-09-14 1997-04-01 Universitat Tubingen Recombinant polypeptide based on the primary sequence of the invariant chain with at least one primary sequence of a specific t-cell epitope or a protein derivative and nucleic acids coding for this recombinant polypeptide
AU3307497A (en) * 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
GB0208817D0 (en) 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
ES2396437T3 (es) * 2005-11-30 2013-02-21 University Of Copenhagen Vacuna de nucleótidos
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
US9085638B2 (en) * 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
JP5707326B2 (ja) * 2008-09-02 2015-04-30 アンティジェン・エクスプレス・インコーポレーテッドＡｎｔｉｇｅｎ Ｅｘｐｒｅｓｓ，Ｉｎｃ． ヒトパピローマウイルス／Ｉｉ−ｋｅｙのハイブリッドおよびその使用方法

Also Published As

Publication number Publication date
IL212914A0 (en) 2011-07-31
PT2865387T (pt) 2019-09-27
IL233176A0 (en) 2014-07-31
EP2355842A1 (en) 2011-08-17
IL233175A0 (en) 2014-07-31
CN107090472A (zh) 2017-08-25
JP2012509071A (ja) 2012-04-19
LT2865387T (lt) 2019-09-25
CA2743229A1 (en) 2010-05-27
DK2865387T3 (da) 2019-08-26
US20150056227A1 (en) 2015-02-26
EP2865387A2 (en) 2015-04-29
EP3552622A3 (en) 2019-12-04
CN102292102A (zh) 2011-12-21
US20210386842A1 (en) 2021-12-16
JP2017131220A (ja) 2017-08-03
CN104404068A (zh) 2015-03-11
AU2009317691A1 (en) 2010-05-27
WO2010057501A1 (en) 2010-05-27
JP2015061530A (ja) 2015-04-02
HK1209645A1 (en) 2016-04-08
JP2019146588A (ja) 2019-09-05
EP2865387A3 (en) 2016-02-24
ES2743677T3 (es) 2020-02-20
SI2865387T1 (sl) 2019-10-30
HRP20191594T1 (hr) 2019-11-29
CY1122117T1 (el) 2020-11-25
RU2017138373A (ru) 2019-02-11
BRPI0921927B8 (pt) 2021-08-31
EP2865387B1 (en) 2019-06-12
IL233174A0 (en) 2014-08-03
BRPI0921927A2 (pt) 2016-04-26
RU2011125306A (ru) 2012-12-27
HUE045093T2 (hu) 2019-12-30
JP6825036B2 (ja) 2021-02-03
BRPI0921927B1 (pt) 2021-06-15
US20110293704A1 (en) 2011-12-01
US20170290898A1 (en) 2017-10-12
EP3552622A2 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
IL233176A0 (en) activation of an immune response
PL2125011T3 (pl) Stymulacja odpowiedzi immunologicznej przez lipidy kationowe
PL2367584T3 (pl) Przyrząd do wskazywania zalania linii infuzyjnej
HUE031343T2 (hu) Immunitásindukáló ágens
IL211341A0 (en) 2-oxo-1,2-dihydro-quiydro-quinoline modulators of immune function
ZA201005042B (en) Spray-dried emulsion
ZA201008536B (en) Suppression of neuroendocrine diseases
GB0803366D0 (en) Nose cone assembly
IL212119A0 (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
PT2213301T (pt) Indutor de resposta imune
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
EP2474315A4 (en) IMMUNITÄTSINDUZIERER
GB0805312D0 (en) Modulation of the immune response
ZA201004979B (en) Extracts of sclerocarya birrea
GB2476767B (en) Method of modifying the immune response
KR101771229B9 (ko) 인젝터 어셈블리
EP2331490A4 (en) PREPARATION OF DIBUTOXYMETHANE
GB201008945D0 (en) An injector
HK1160006A (en) Priming of an immune response
HK1158524A (en) Method of inducing an anti-viral immune response
AU2010902717A0 (en) Stimulating immune response
GB0911664D0 (en) Compounds and methods for the suppression of an immune response
TWM301017U (en) Assembly of infusing cup set
GB0807824D0 (en) Patient specific immune desensitisation
GB0810785D0 (en) Suppression of neuroendocrine diseases